News | July 03, 2012

FSS Announces CE Mark for its FlexStent Iliac Self Expanding Stent System

July 3, 2012 — Flexible Stenting Solutions Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced that it has extended its CE mark authorized family of peripheral vascular stents to include the FlexStent iliac self expanding stent system.

The FlexStent iliac self expanding stent system is indicated for the treatment of symptomatic atherosclerotic disease of the common and/or external iliac arteries. With this product line extension, the FlexStent family of peripheral vascular stent systems now includes stent diameters of 5, 6, 7, 8, 9 and 10 mm, and offers the physician additional options in the treatment of patients with peripheral artery disease (PAD) of the iliac, superficial femoral and popliteal arteries.

The addition of the FlexStent iliac self expanding stent system to the FSS CE mark authorized family of peripheral vascular stents enhances marketing opportunities for FSS products in the European medical device space. Market launch of the FlexStent iliac self expanding stent system in Europe is expected in Q3 2012.

As with the FlexStent femoropopliteal self expanding stent system, the FlexStent iliac self expanding stent system is an innovative, nearly fully connected, flexible, strong and durable nitinol stent delivered from a straightforward stent delivery system. In addition to simplicity and ease of use, the 6 French / .035" over the wire delivery system provides the physician with a means for very accurate stent deployment.

For more information: www.flexiblestent.com

Related Content

The Pedra Blood Perfusion Index tracks real-time changes in foot tissue perfusion attendant with balloon inflation and deflation during an angioplasty procedure.

The Pedra Blood Perfusion Index tracks real-time changes in foot tissue perfusion attendant with balloon inflation and deflation during an angioplasty procedure.

News | Peripheral Artery Disease (PAD) | January 26, 2021
January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S.
The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices. 

The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices. 

News | Peripheral Artery Disease (PAD) | November 13, 2020
November 13, 2020 — The new U.S.
he 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent showed low rates of revascularization and compared very favorably to current standards of care.  The results were presented by Professor Thomas Zeller, M.D., University Heart Centre Freiburg, Bad Krozingen, Germany at the CX 2020 Live conference.   
News | Peripheral Artery Disease (PAD) | June 16, 2020
June 16, 2020 — The 36-month results from Veryan Medical’s MIMICS-2 study for the BioMimics 3D femoropopliteal stent
The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

News | Peripheral Artery Disease (PAD) | March 28, 2020
March 28, 2020 — People with symptomatic...
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 7, 2019 — Ultrasoundplasty before angioplasty for below-the-knee lesions (BTK) lesions may improve clinical
News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — There were positive results in the TANGO Trial is a phase 2, dose escalation, double-blinded tria
The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot.  #VIVA #VIVA19 #VIVA2019

The LimFlow procedure permanently bypasses unreconstructable arteries and leverages healthier veins as a conduit to create new routes to perfuse tissue in the foot. 

News | Peripheral Artery Disease (PAD) | November 14, 2019
November 14, 2019 — Results were positive for the multicenter PROMISE I Trial represents the first human use in the U
Eluvia and Ranger PAD devices from Boston Scientific. #VIVA19 #VIVA2019 #VIVA
News | Peripheral Artery Disease (PAD) | November 06, 2019
November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-elutin
FDA Panel Recommends Continued Use of Paclitaxel-coated Peripheral Devices
Feature | Peripheral Artery Disease (PAD) | August 28, 2019 | Jeff Zagoudis, Associate Editor
The U.S. Food and Drug Administration (FDA) released an updated MedWatch Alert this month on the safety of paclitaxel-...